The study duration is one year; post treatment safety follow up visit will be conducted 4 weeks after the patient takes the last dose of teriflunomide
Primary Objective:~To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis.~Secondary Objective:~To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.